Inferring restrictions in the temporal order of mutations during tumor progression: effects of passengers, evolutionary models, and sampling

Abstract

Cancer progression is caused by the sequential accumulation of mutations, but not all orders of accumulation of mutations are equally likely. When the fixation of some mutations depends on the presence of previous ones, identifying restrictions in the order of accumulation of mutations can lead to the discovery of therapeutic targets and diagnostic markers. Using simulated data sets, I conducted a comprehensive comparison of the performance of all available methods to identify these restrictions from cross-sectional data. In contrast to previous work, I embedded restrictions within evolutionary models of tumor progression that included passengers (mutations not responsible for the development of cancer, known to be very common). This allowed me to asses the effects of having to filter out passengers, of sampling schemes, and of deviations from order restrictions. Poor choices of method, filtering, and sampling lead to large errors in all performance metrics. Having to filter passengers lead to decreased performance, especially because true restrictions were missed. Overall, the best method for identifying order restrictions were Oncogenetic Trees, a fast and easy to use method that, although unable to recover dependencies of mutations on more than one mutation, showed good performance in most scenarios, superior to Conjunctive Bayesian Networks and Progression Networks. Single cell sampling provided no advantage, but sampling in the final stages of the disease vs. sampling at different stages had severe effects. Evolutionary model and deviations from order restrictions had major, and sometimes counterintuitive, interactions with other factors that affected performance. This paper provides practical recommendations for using these methods with experimental data. Moreover, it shows that it is both possible and necessary to embed assumptions about order restrictions and the nature of driver status within evolutionary models of cancer progression to evaluate the performance of inferential approaches.